Alligator Bioscience AB (FRA:7AL0) Accounts Payable: €0.41 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7AL0 Alligator Bioscience AB FRA:7AL0
41 GF Score
Price €0.00
! 7 Warning Signs
View Full Analysis

What is Alligator Bioscience AB Accounts Payable?

Alligator Bioscience AB FRA:7AL0 41 Accounts Payable is €0.41 Mil as of Mar. 2026. GuruFocus rates FRA:7AL0 with a GF Score™ of 41/100. The stock has 7 warning signs investors should review.

Alligator Bioscience AB's Accounts Payable for the quarter that ended in Mar. 2026 was €0.41 Mil.

Alligator Bioscience AB's quarterly Accounts Payable declined from Sep. 2025 (€0.58 Mil) to Dec. 2025 (€0.42 Mil) and declined from Dec. 2025 (€0.42 Mil) to Mar. 2026 (€0.41 Mil).

Alligator Bioscience AB's annual Accounts Payable declined from Dec. 2023 (€1.90 Mil) to Dec. 2024 (€0.34 Mil) but then increased from Dec. 2024 (€0.34 Mil) to Dec. 2025 (€0.42 Mil).

Alligator Bioscience AB Accounts Payable Related Terms

Alligator Bioscience AB Accounts Payable Historical Data

* Premium members only.

The historical data trend for Alligator Bioscience AB's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alligator Bioscience AB Accounts Payable Chart

Alligator Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.91 1.21 1.90 0.34 0.42

Alligator Bioscience AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.90 0.58 0.42 0.41
FRA:7AL0
41GF Score
Alligator Bioscience AB FRA:7AL0
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alligator Bioscience AB Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €0.41 Mil mean?
Alligator Bioscience AB (FRA:7AL0) has a Accounts Payable of €0.41 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Alligator Bioscience AB and its competitors.
Is Alligator Bioscience AB's Accounts Payable too high?
Alligator Bioscience AB's current Accounts Payable is €0.41 Mil. Overall, Alligator Bioscience AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Alligator Bioscience AB's Accounts Payable compare to VRTX and REGN?
Alligator Bioscience AB's Accounts Payable of €0.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Alligator Bioscience AB and its competitors. Alligator Bioscience AB's current Accounts Payable is €0.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Alligator Bioscience AB (FRA:7AL0) has a current Accounts Payable of €0.41 Mil. The current Accounts Payable is €0.41 Mil. Alligator Bioscience AB's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Alligator Bioscience AB (FRA:7AL0), the current Accounts Payable is €0.41 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alligator Bioscience AB Business Description

Other Exchanges ATORX:Sweden0RK9:UK
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
41GF Score

Get the complete analysis for FRA:7AL0

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.00
Price